Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.38 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900511 | 1.00 | ADRA1D (0.38) | ADRA1DSLC10A2SLC6A2SLC6A4NOS3 | |
| SCHEMBL12651546 | 1.00 | ADRA1D (0.38) | ADRA1DSLC10A2SLC6A2SLC6A4NOS3 | |
| SCHEMBL19117718 | 0.80 | SLC6A2 (0.40) | SLC10A2SLC6A2SLC6A4NOS3NOS1 | |
| SCHEMBL21266523 | 0.80 | SLC6A2 (0.40) | SLC10A2SLC6A2SLC6A4NOS3NOS1 | |
| SCHEMBL12180971 | 0.80 | SLC6A2 (0.40) | SLC10A2SLC6A2SLC6A4NOS3NOS1 | |
| SCHEMBL12609032 | 0.78 | ADRA1D (0.36) | ADRA1DSLC10A2SLC6A2SLC6A4BRCA1 | |
| SCHEMBL13059132 | 0.78 | ADRA1D (0.36) | ADRA1DSLC10A2SLC6A2SLC6A4BRCA1 | |
| SCHEMBL12609028 | 0.78 | ADRA1D (0.36) | ADRA1DSLC10A2SLC6A2SLC6A4BRCA1 | |
| SCHEMBL13499160 | 0.77 | CA2 (0.41) | ADRA1DSLC10A2SLC6A2SLC6A4CA2 | |
| SCHEMBL2906600 | 0.77 | CA2 (0.41) | ADRA1DSLC10A2SLC6A2SLC6A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20210380591-A1 | ANTHELMINTIC HETEROCYCLIC COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | ADRA1D 3194/4885SLC10A2 3679/4885SLC6A2 4007/4885 |
| US-20210380591-A1 | ANTHELMINTIC HETEROCYCLIC COMPOUNDS | AADAC, HNMT, HRH4 | ADRA1D 4566/4885SLC10A2 274/4885SLC6A2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.